Company news
Forte Biosciences, Inc. (NASDAQ:FBRX) news
Forte Biosciences, Inc. news releases on 6ix. Latest, Jul 9, 2026: FB102 Achieves Statistically Significant Improvement in Vitiligo at Week 24 After…
Press releases & updates
FB102 Achieves Statistically Significant Improvement in Vitiligo at Week 24 After Completion of 12-Week Treatment Period
July 9, 2026
Forte Biosciences, Inc. Announces First Quarter 2026 Results and Provides Update
May 11, 2026
Forte Biosciences Announces Pricing of $150 Million Public Offering
April 7, 2026
Forte Biosciences, Inc. Announces 2025 Results and Provides Update
March 30, 2026
Forte Biosciences, Inc. Reports Inducement Grants Under NASDAQ Listing Rules
March 3, 2026
Forte Biosciences, Inc. to Present at Upcoming Investor Meetings
February 9, 2026
Forte Biosciences, Inc. Reports Inducement Grant Under Nasdaq Listing Rules
December 22, 2025
Forte Biosciences, Inc. Announces Third Quarter 2025 Results and Provides Update
November 14, 2025
Forte Biosciences Inc. Reports Inducement Grants Under Nasdaq Listing Rules
October 6, 2025
Forte Biosciences, Inc. Reports Inducement Grants Under Nasdaq Listing Rules
October 3, 2025
Forte Biosciences, Inc. Announces Presentation of FB102 Celiac Disease Trial at Tampere Celiac Disease Symposium
September 15, 2025
Forte Biosciences, Inc. Announces Results and Provides Update
August 14, 2025
Forte Biosciences Announces Pricing of $75 Million Public Offering
June 25, 2025
Forte Biosciences Announces Proposed Public Offering
June 24, 2025
Forte Biosciences Announces Positive Data in FB102 Celiac Disease Phase 1B Study
June 23, 2025
Forte Biosciences, Inc. Announces Results and Provides Clinical Update
March 31, 2025
Forte Biosciences to Host R&D Day December 3, 2024
November 24, 2024
Forte Biosciences, Inc. Announces Oversubscribed $53 Million Private Placement From Leading Healthcare Institutional Investors to Advance FB102 Across Autoimmune Indications
November 19, 2024
Forte Biosciences, Inc. Announces Third Quarter 2024 Results and Provides Business Update
November 13, 2024
Forte Biosciences, Inc. Announces Second Quarter 2024 Results and Provides Business Update
August 13, 2024
Forte Biosciences, Inc. Announces First Quarter 2024 Results and Provides Business Update
May 12, 2024
Forte Biosciences, Inc. Announces 2023 Results and Provides Business Update
March 17, 2024
Forte Biosciences, Inc. Announces Third Quarter 2023 Results and Provides Business Update
November 12, 2023
Forte Biosciences, Inc. Announces Second Quarter 2023 Results and Provides Business Update
August 13, 2023
Forte Biosciences, Inc. Announces $25 Million Financing and R&D Update for FB-102
July 31, 2023
Forte Biosciences, Inc. Announces First Quarter 2023 Results and Provides Business Update
May 14, 2023
Forte Biosciences, Inc. Announces Full Year 2022 Results and Provides Business Update
March 30, 2023
Mr. David Gryska Appointed to Forte Biosciences Board of Directors
January 11, 2023
Forte Biosciences, Inc. Announces Third Quarter 2022 Results and Provides Business Update
November 13, 2022
Dr. Scott Brun, M.D. Appointed to Forte Biosciences Board of Directors
November 13, 2022
Forte Biosciences, Inc. Announces Second Quarter 2022 Results and Provides Business Update
August 14, 2022
Forte Biosciences, Inc. Announces the Appointment of Dr. Hubert Chen, MD as Chief Scientific Officer and President
June 6, 2022
Forte Biosciences, Inc. Announces First Quarter 2022 Results and Provides Business Update
May 15, 2022
Forte Biosciences, Inc. Announces First Quarter 2021 Results and Provides a General Business Update
May 9, 2021
Forte Biosciences, Inc. Announces 4Q and Full Year 2020 Results and Provides a General Business Update
March 23, 2021
Forte Biosciences, Inc. Announces Third Quarter 2020 Results and Provides General Business Update
November 8, 2020
Forte Biosciences, Inc. to Announce Third Quarter 2020 Results on November 9
November 1, 2020
Forte Biosciences Announces Closing of $46.0 Million Public Offering of Common Stock and Full Exercise of Underwriters’ Option to Purchase Additional Shares
November 1, 2020
Forte Biosciences Announces Pricing of $40.0 Million Public Offering of Common Stock
October 28, 2020
Forte Biosciences Announces Proposed Public Offering of Common Stock
October 27, 2020
Forte Biosciences, Inc. Announces the FDA Has Granted Fast Track Designation to FB-401 for the Treatment of Atopic Dermatitis
October 25, 2020
Forte Biosciences, Inc. Announces First Patient Dosed in the Clinical Trial of FB-401 for the Treatment of Children and Adults With Atopic Dermatitis
September 28, 2020
Forte Biosciences, Inc. Announces Full Publication of Phase 1/2 Data in Science Translational Medicine
September 8, 2020
Forte Biosciences, Inc. Announces Second Quarter 2020 Results and Provides General Business Update
August 9, 2020
Forte Biosciences, Inc. to Announce Second Quarter 2020 Results on August 10
August 2, 2020
Forte Biosciences, Inc. Announces Issuance of New U.S. Patent
June 17, 2020